StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
BDXBullishIndustry Newsnews
High materiality7/10

BD completes enrollment in pivotal PREVENT trial for Phasix Mesh

Aug 12, 2026, 6:55 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Milestone completion reduces regulatory uncertainty and could unlock a path to FDA submission; successful data could broaden BD's TAM in surgical repair, supporting multiple-year growth catalysts, though near-term earnings impact remains uncertain.

AI summary

What happened, with direct paths to the underlying reporting

BD announced enrollment completion in PREVENT, the first large randomized trial of Phasix Mesh to prevent incisional hernias after open abdominal surgery. The study enrolled 477 patients across 32 sites in the US and Europe, with a 24-month primary endpoint and up to five years of follow-up, potentially supporting an FDA submission for this indication.

  • Enrollment completed in PREVENT trial evaluating Phasix Mesh for incisional hernia prevention. 477 patients across 32 sites in US/Europe.
  • Largest randomized prophylactic mesh trial; aims to support FDA submission. Primary endpoint at 24 months; long-term follow-up to five years.
  • Phasix Mesh is a resorbable mesh. BD aims to expand regenerative tech in surgery.
  • Primary endpoint readout planned at 24 months; data could support regulatory filing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event